Sign in and upgrade to a paid plan to export NAV history as CSV.

Akums Drugs and Pharmaceuticals Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: AKUMS BSE: 544222
₹818.50
▼ -1.05 (-0.13%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
66/100
Moderate
Valuation
21/100
Expensive
Momentum
87/100
Bullish

QVM read Momentum-led Quality Moderate, Valuation Expensive, Momentum Bullish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

About

Akums Drugs and Pharmaceuticals Limited (Akums Group) is an Indian pharmaceutical Contract Development and Manufacturing Organization (CDMO) that serves both domestic and multinational pharmaceutical companies. The company was established in 2004 and became publicly listed on 6 August 2024.

Source: Wikipedia

Key Metrics

Market Capitalization
₹12,883 Cr
PE (TTM)
112.3
Industry median 36.1 (152 companies)
Price to Book
3.9
PEG (TTM)
-3.5
Institutions holding %
15.35%
FII + DII, latest filed period
Piotroski Score
4
Relative return vs Nifty50, qtr %
48.1
Relative return vs Sector, qtr %
29.7
Free Cash Flow
₹951 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
0.00%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-31.94%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
6.15%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-0.06%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
18.00%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
3.25
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.02
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
16.43
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
11.43%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
15.76%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
11.20%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
4.71%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
10.94%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
7.70%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

1 of 8 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 4)
  • Yes Debt to equity is below 0.5 (0.02)
  • No Return on equity is 15% or more (7.7%)
  • No Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

3 of 3 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

2 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

3 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Overvalued (above its own historical PE range))
  • No Valuation score is Undervalued (70 or more)
  • Yes Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-0.1%
Low 811.1000 · High 828.2000
1W return
-0.6%
Low 798.0000 · High 836.8000
1M return
5.4%
Low 733.1500 · High 838.8000
52W return
81.4%
Low 409.3000 · High 838.8000
Lifetime High ₹1119.9500 (Aug. 19, 2024)
Lifetime Low ₹414.0500 (Nov. 24, 2025)

Full price history and technicals →

EMA & SMA

Bullish6
Bearish0
5D
814.2
10D
805.9
20D
790.1
50D
747.5
100D
685.3
200D
572.1

Delivery and volume

Day avg. delivery
44.7%
Week avg. delivery
49.4%
Month avg. delivery
52.2%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

819.27
Pivot
First resistance827.43
Second resistance836.37
Third resistance844.53
First support810.33
Second support802.17
Third support793.23
Day RSI61.9
Day MFI75.4
Day MACD21.10
Day MACD signal19.78

Beta

1M1.59
3M0.60
1Y0.93
3Y1.10

Price change analysis

↑ 5.4%
Over 1 Month
LowHigh
733.15838.80
↑ 29.7%
Over 3 Months
LowHigh
620.00838.80
↑ 64.9%
Over 6 Months
LowHigh
479.55838.80
↑ 81.4%
Over 1 Year
LowHigh
409.30838.80
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 112.3 (own history: 43.8–85.5)
Overvalued (above its own historical PE range)
Revenue (June 30, 2026)
₹392 Cr
Net profit (June 30, 2026)
₹45 Cr
Basic EPS (June 30, 2026)
₹2.9300

Ranks #41 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter75.26%
  • Mutual funds9.77%
  • FII/FPI1.91%
  • Other DII3.67%
  • Public6.66%

Largest holders

NameCategoryShares %Shares
AKUMS MASTER TRUST (Sanjeev Jain and Sandeep Jain)Promoter40.7900%64200000
Sandeep JainPromoter17.2400%27127690
Sanjeev JainPromoter17.2300%27113940
Franklin India Opportunites FundPublic4.1900%6592337
Icici Prudential Pharma Healthcare And Diaganostics (P.H.D) FundPublic3.1400%4943282

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 75.26% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 1.37% to 1.91% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings decreased from 10.95% to 9.77% in Jun 2026 qtr

5 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 0 insider trades, 2 SAST, 0 pledge events →

All insider and SAST disclosures →

DateClientDealActionQuantityPriceExchange
22 Dec 2025 RUBY QC INVESTMENT HOLDINGS PTE.LTD. Block Sell 7,278,535 428.0000 NSE
22 Dec 2025 ICICI PRUDENTIAL MUTUAL FUND Block Buy 7,278,535 428.0000 NSE
22 Dec 2025 RUBY QC INVESTMENT HOLDINGS PTE.LTD. Bulk Sell 7,278,535 428.0000 NSE
22 Dec 2025 ICICI PRUDENTIAL MUTUAL FUND Bulk Buy 7,278,535 428.0000 NSE
22 Dec 2025 RUBY QC INVESTMENT HOLDINGS PTE.LTD. Block Sell 7,278,535 428.0000 NSE
22 Dec 2025 ICICI PRUDENTIAL MUTUAL FUND Block Buy 7,278,535 428.0000 NSE
6 Aug 2024 SMALLCAP WORLD FUND INC Bulk Buy 2,586,541 753.8400 NSE

All bulk and block deals →

Last 12 months ₹1.00 per share
Dividend yield 0.12%
Ex-dateSubjectPer share (₹)Record date
3 Jul 2026 Dividend - Re 1 Per Share/Special Dividend - Rs 2 Per Share 1.0000 3 Jul 2026

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
8 Aug 2026 Financial Results Yes
14 May 2026 Dividend —
14 May 2026 Financial Results Yes
13 Feb 2026 Financial Results Yes
13 Nov 2025 Financial Results Yes

Corporate Announcements

All 206 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
25 Sep 2026 Trading Window Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
25 Sep 2026 Insider Trading / SAST Akums Drugs and Pharmaceuticals Ltd - 544222 - Closure of Trading Window
23 Sep 2026 Analysts/Institutional Investor Meet/Con. Call Updates Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
16 Sep 2026 Company Update Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
16 Sep 2026 Analysts/Institutional Investor Meet/Con. Call Updates Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
3 Sep 2026 General Updates Intimation of ESG Rating
25 Aug 2026 Analysts/Institutional Investor Meet/Con. Call Updates Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
24 Aug 2026 Analysts/Institutional Investor Meet/Con. Call Updates Akums Drugs and Pharmaceuticals Limited has informed the Exchange about an Update on schedule of the Investors/ Analysts Meet to be held on August 25, 2026
13 Aug 2026 Analysts/Institutional Investor Meet/Con. Call Updates Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
13 Aug 2026 Analysts/Institutional Investor Meet/Con. Call Updates Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Transcript

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.02)
  • Comfortable interest coverage (16.4x)
  • Strong revenue growth YoY (18.0%)

Weaknesses

  • Low Return on Equity (7.7%)
  • Declining profit YoY (-0.1%)

Opportunities

Data unavailable.

Threats

  • PE above 35 (112.3) -- priced for continued strong execution

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Akums Drugs and Pharmaceuticals Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.